Lost on me | NBIX Message Board Posts

Neurocrine Biosciences, Inc.

  NBIX website

NBIX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  47763 of 47799  at  4/7/2021 7:24:09 PM  by

goirish1776

The following message was updated on 4/7/2021 7:25:43 PM.

Lost on me

 From Q4 Earnings:
 
"Furthermore, we plan to initiate trials with valbenazine this year in two new areas of interest, with registration phase studies in both the neurological and psychiatric indication."
 
"I'll begin with NBI-827104 or 104 for short. 104, a potent and highly selective T-type calcium channel antagonist, is currently enrolling patients in a Phase II study for epileptic encephalopathy with Continuous Spike and Wave during Sleep. 104 has the potential to expand into a range of other central nervous system disease areas. And we are moving forward with the initiation of a Phase II study in the first of these additional neurological indications this year."
 
"Turning now to NBI-921352, or simply 352...We also plan to initiate a Phase II study of 352 for the treatment of adult focal epilepsy this year. As a result, with our two precision medicine candidates, 104 and 352, we'll have trials underway in four distinct neurological disorders this year.
 
I missed all that - 3 molecules, 4 new indications, 2 new registrational trials (Ingrezza).  Will look forward all the data in the coming year or two. 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...